Rosen Law Firm reminds investors of Park Ha Biological Technology Co., Ltd. (NASDAQ: PHH, BYAH) of lead plaintiff opportunity in securities class action covering Dec 27, 2024–Jul 8, 2025 purchases

Executive summary: Rosen Law Firm reminded purchasers of Park Ha Biological Technology Co., Ltd. (NASDAQ: PHH, BYAH) securities between December 27, 2024 and July 8, 2025 of their opportunity to lead the securities class action lawsuit, with a lead plaintiff deadline of September 28, 2026. The reminder reactivates investor awareness of a significant securities claim alleging IPO-related misconduct and a 93% stock collapse, potentially influencing shareholder behavior and litigation strategy ahead of the September 28 deadline.

Who is involved: Key actors include Rosen Law Firm (plaintiffs' counsel), Park Ha Biological Technology Co., Ltd. (defendant), investors who purchased PHH/BYAH shares during the class period, and the court overseeing the class action.

Likely next: Investors may file motions to be appointed lead plaintiff before the September 28, 2026 deadline; if appointed, the lead plaintiff will direct litigation strategy, potentially leading to discovery, settlement talks, or trial preparation.

The Rosen Law Firm issued a notice on August 11, 2026, reminding investors who purchased Park Ha Biological Technology Co., Ltd. securities during the specified class period of their right to seek appointment as lead plaintiff in an ongoing securities class action. The lawsuit stems from allegations related to the company's IPO structure and subsequent 93% single-session stock collapse. No new factual developments in the litigation were announced beyond the reminder of investor rights and the September 28, 2026 lead plaintiff deadline.

What's next — scenarios

Litigation Deadlock (50%)

Capital remains locked in legal escrow with no recovery for investors in the near term.

No lead plaintiff appointed by Sept 28 deadline
Court delays appointment hearings

Class Action Settlement (35%)

Partial recovery of principal for shareholders at a fraction of the loss, limiting downside risk.

Announcement of lead plaintiff appointment
Motion to dismiss denied by court

Judgment Against Company (15%)

Significant liquidity drain for Park Ha Biological Technology due to massive legal liabilities.

Certification of class status
Successful completion of discovery phase

What to watch

Sept 28, 2026: Deadline for lead plaintiff applications
Oct 2026: Court ruling on lead plaintiff appointment
Q3 2026: PHH/BYAH regulatory filings regarding litigation reserves

Timeline

2026-08-11 — PHH, BYAH Investors Have Opportunity to Lead Park Ha Biological Technology Co., Ltd. Securities Lawsuit (PR Newswire)
2026-08-11 — BYAH DEADLINE: The Gross Law Firm Reminds Park Ha Biological Technology Co., Ltd. Investors of Upcoming Securities Class Action Deadline (PR Newswire)

Analysis — what this means

Likely next events

September 28, 2026: Deadline for investors to move for appointment as lead plaintiff in the PHH/BYAH securities class action

Sectors affected

Biotechnology
Specialty Chemicals
Consumer Skincare

Regulatory implications

Securities class actions under Rule 10b-5 may proceed if plaintiffs adequately plead falsity and scienter related to IPO disclosures
Lead plaintiff appointment affects litigation control and potential settlement leverage under PSLRA
Ongoing case may inform SEC scrutiny of IPO structures with low public float and affiliated promotional schemes

Historical parallels

Similar to the 2021 Gaiam class action (NASDAQ: GAIA) where IPO disclosure issues led to securities litigation
Analogous to 2020 Luckin Coffee incident where financial irregularities triggered investor lawsuits and delisting

Key entities

Sources

Related cases

Browse the full archive →